Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects

Diabetologia

Volumn 43, Issue 5, 2000, Pages 673-680

  Flavell, D M ^a   Pineda Torra, I ^b   Jamshidi, Y ^a   Evans, D ^c   Diamond, J R ^d   Elkeles, R S ^d   Bujac, S R ^e   Miller, G ^e   Talmud, P J ^a   Staels, B ^b   Humphries, S E ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b INSTITUT PASTEUR DE LILLE   (France)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^e MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Dyslipidaemia; Nuclear receptors; Polymorphism; PPAR ; Type II diabetes

Indexed keywords

CELL NUCLEUS RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; APOLIPOPROTEIN A1; BEZAFIBRATE; CELL RECEPTOR; CHOLESTEROL; DNA; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; SINGLE STRAND CONFORMATION POLYMORPHISM; BINDING SITE; BLOOD; GENETIC TRANSFECTION; GENETICS; INTRON; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; PHYSIOLOGY; PROSPECTIVE STUDY;

APOLIPOPROTEIN A-I; BEZAFIBRATE; BINDING SITES; CHOLESTEROL; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DNA; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; INTRONS; LIPIDS; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROSPECTIVE STUDIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0034182779     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051357     Document Type: Article

References (44)

1. 1. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68: 879-887
2. 2. Schonfeld G (1994) The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 111: 161-174
3. 3. Fruchart J, Duriez P, Staels B (1999) Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10: 245-257
4. 4. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W (1996) The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384: 39-43
5. 5. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406-3410
6. 6. Krey G, Braissant O, L'Horset F et al. (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11: 779-791
7. 7. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137: 354-366
8. 8. Staels B, Koenig W, Habib A et al. (1998) Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARg activators. Nature 393: 790-793
9. 9. Inoue I, Shino K, Noji S, Awata T, Katayama S (1998) Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 246: 370-374
10. 10. Chinetti G, Griglio S, Antonucci M et al. (1998) Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273: 25573-25580
11. 11. Frick MH, Syvanne M, Nieminen MS et al. (1997) Prevention of the angiographic progression of coronary and veingraft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96: 2137-2143
12. 12. Oliver MF, Heady JA, Morris JN, Cooper J (1980) W. H. O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet ii:379-385
13. 13. Frick MH, Elo O, Haapa K et al. (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237-1245
14. 14. Betteridge DJ (1996) Lipids and atherogenesis in diabetes mellitus. Atherosclerosis 124[Suppl]:S43-S47
15. 15. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-444
16. 16. Elkeles RS, Diamond JR, Poulter C et al. (1998) Cardiovascular Outcomes in Type 2 Diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Baling, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 21: 641-648
17. 17. Lee SS, Pineau T, Drago J et al. (1995) Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15: 3012-3022
18. 18. Peters JM, Hennuyer N, Staels B et al. (1997) Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 272: 27307-27312
19. 19. Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T (1998) Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 273: 29577-29585
20. 20. Kroetz DL, Yook P, Costet P, Bianchi P, Pineau T (1998) Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction response to starvation and diabetes. J Biol Chem 273: 31581-31589
21. 21. Djouadi F, Weinheimer CJ, Saffitz JE et al. (1998) A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice. J Clin Invest 102: 1083-1091
22. 22. Skronowski R, Hollenbeck CB, Varasteh CB, Chen Y, Reaven GM (1991) Regulation of non-esterified fatty acid and glycerol concentration by insulin in normal individuals and patients with type 2 diabetes. Diabet Med 8: 330-333
23. 23. Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD (1996) Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost 75: 767-771
24. 24. Gudnason V, Mak YT, Betteridge J, McCarthy SN, Humphries S (1993) Use of the single-strand conformational polymorphism method to detect recurrent and novel mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolaemia: detection of a novel mutation Asp200 →Gly. Clin Investig 71: 331-337
25. 25. Day IN, Humphries SE (1994) Electrophoresis for geno-typing: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem 222: 389-395
26. 26. Vu Dac N, Schoonjans K, Kosykh V et al. (1995) Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96: 741-750
27. 27. Sher T, Yi HF, McBride OW, Gonzalez FJ (1993) cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32: 5598-5604
28. 28. Mukherjee R, Jow L, Noonan D, McDonnell DP (1994) Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol 51: 157-166
29. 29. Gearing KL, Crickmore A, Gustafsson JA (1994) Structure of the mouse peroxisome proliferator activated receptor alpha gene. Biochem Biophys Res Commun 199: 255-263
30. 30. Steineger HH, Sorensen HN, Tugwood JD, Skrede S, Spydevoid O, Gautvik KM (1994) Dexamethasone and insulin demonstrate marked and opposite regulation of the steady-state mRNA level of the peroxisomal proliferator-activated receptor (PPAR) in hepatic cells. Hormonal modulation of fatty-acid-induced transcription. Eur J Biochem 225: 967-974
31. 31. Shalev A, Siegrist Kaiser CA, Yen PM et al. (1996) The peroxisome proliferator-activated receptor alpha is a phosphoprotein: regulation by insulin. Endocrinology 137: 4499-4502
32. 32. Staels B, Vu Dac N, Kosykh VA et al. (1995) Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95: 705-712
33. 33. Vu Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B (1994) Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 269: 31012-31018
34. 34. Berthou L, Duverger N, Emmanuel F et al. (1996) Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 97: 2408-2416
35. 35. Staels B, Auwerx J (1998) Regulation of apo A-I gene expression by fibrates. Atherosclerosis 137[Suppl]:S19-S23
36. 36. Vu Dac N, Chopin Delannoy S, Gervois P et al. (1998) The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 273: 25713-25720
37. 37. Garg A, Grundy S (1990) Management of dyslipidemia in NIDDM. Diabetes Care 13: 153-169
38. 38. Jeck T, Riesen WF, Keller U (1997) Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM. Diabet Med 14: 564-570
39. 39. Laakso M, Lehto S, Penttila I, Pyorala K (1993) Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 88: 1421-1430
40. 40. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M (1997) Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 48: 1354-1359
41. 41. Florkowski CM, Scott RS, Moir CL, Graham PJ (1998) Lipid but not glycaemic parameters predict total mortality from type 2 diabetes mellitus in Canterbury, New Zealand. Diabet Med 15: 386-392
42. 42. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [published erratum appears in Diabetes Care 1997 Jun; 20: 1048] Diabetes Care 20: 614-620
43. 43. Hsu MH, Palmer CN, Song W, Griffin KJ, Johnson EF (1998) A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding. J Biol Chem 273: 27988-27997
44. 44. Juge-Aubry C, Pernin A, Favez T et al. (1997) DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5′-flanking region. J Biol Chem 272: 25252-25259